Basic science is research driven by curiosity about how the natural world works, without an immediate practical goal in mind. It is the kind of investigation that asks “what is this?” or “how does this happen?” rather than “how can we fix this problem?” The distinction sounds abstract until you trace the origins of nearly every modern medical treatment, digital technology, or agricultural advance back to a lab where someone was simply trying to understand something fundamental. That trail from curiosity to consequence is what makes basic science matter, and the story is richer and more surprising than most people realize.
What Counts as Basic Science
The simplest way to think about basic science is research motivated by the desire to understand something, not to build or sell something. A physicist studying how electrons behave in certain materials is doing basic science. A biologist cataloging the immune defenses of bacteria is doing basic science. Neither expects a product to come out of the work next year, or maybe ever. The goal is knowledge itself.
That said, the line between “basic” and “applied” is blurrier than textbook definitions suggest. In the 1990s, political scientist Donald Stokes proposed a framework that has become influential in science policy circles. Rather than placing basic and applied research on opposite ends of a single spectrum, Stokes argued they sit on two independent axes: one measuring the quest for fundamental understanding, the other measuring consideration of practical use. This creates a grid where some research is purely curiosity-driven with no eye toward use (he pointed to Niels Bohr’s work on atomic structure as an example), some is purely use-driven with no interest in deeper understanding (Thomas Edison’s invention of the light bulb), and some pursues both at once. Louis Pasteur’s microbiology work, which simultaneously advanced fundamental knowledge about microorganisms and led directly to vaccines, occupied that dual-purpose space.1PNAS Nexus. At the nexus of science, engineering, and medicine: Pasteur’s quadrant reconsidered
The practical takeaway from Stokes’s framework is that basic science is not defined by being useless. It is defined by its motivation. Researchers doing basic science follow questions wherever they lead, without requiring that the answers serve an immediate commercial or clinical purpose. Sometimes those answers turn out to be enormously useful. Sometimes they sit in journals for decades before anyone realizes what they are worth.
From Bacterial Immune Systems to Gene Editing
Few stories illustrate the unpredictable payoff of basic science better than CRISPR. In the late 1980s and 1990s, microbiologists noticed strange repeating DNA sequences in bacteria and archaea. They had no reason to think this observation would ever matter to medicine. Researchers gradually figured out that these sequences were part of an adaptive immune system that prokaryotes use to defend themselves against viruses. Bacteria essentially store snippets of viral DNA so they can recognize and destroy the same virus if it shows up again.2PubMed Central. CRISPR-Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing
That insight, born of pure curiosity about microbial biology, eventually led researchers to realize that the CRISPR-Cas9 system could be reprogrammed to cut any DNA sequence, making it possible to edit the genome of virtually any organism with unprecedented precision.3PubMed. CRISPR-Cas9: A fascinating journey from bacterial immune system to human gene editing The technology is now being used in clinical trials for sickle cell disease, certain cancers, and inherited blindness, and it has already produced the first FDA-approved gene-editing therapy.
Nobody funding those early microbiology studies was thinking about human therapeutics. The researchers were not trying to cure anything. They wanted to know what those odd DNA repeats were for. The entire CRISPR revolution grew from that question. This is the pattern basic science follows again and again: the time between a fundamental discovery and its first practical use can span decades, and the application often belongs to a field the original researchers never imagined.
How Basic Science Underpins Drug Development
The pharmaceutical industry is sometimes portrayed as the engine of medical innovation, and it does play a critical role in developing, testing, and manufacturing drugs. But the foundational research that identifies drug targets in the first place overwhelmingly comes from publicly funded basic science, most of it supported by the National Institutes of Health.
A landmark study looking at the 210 new drugs approved by the FDA from 2010 to 2016 found that NIH funding contributed to published research associated with every single one of them. The funding was focused primarily on understanding the biological targets those drugs act on, rather than on developing the drugs themselves. Over the period studied, this basic research represented more than 200,000 fiscal years of NIH project support and over $100 billion in project costs.4PubMed Central. Contribution of NIH funding to new drug approvals 2010-2016
A follow-up analysis extended the window to 2010–2019 and found essentially the same thing: NIH funding contributed to 354 of 356 drugs approved in that decade, totaling roughly $187 billion in public investment. The study also compared what the government spent per approval to what industry spent and found that for drugs hitting entirely new biological targets, NIH spending was significantly greater than reported industry spending.5PubMed Central. Comparison of Research Spending on New Drug Approvals by the National Institutes of Health vs the Pharmaceutical Industry, 2010-2019 A related working paper characterized overall NIH funding associated with those 356 drugs at $230 billion, describing the government as effectively “the first investor” in the biopharmaceutical innovation pipeline.6Institute for New Economic Thinking Working Paper Series. Government as the First Investor in Biopharmaceutical Innovation: Evidence From New Drug Approvals 2010–2019
This does not mean the private sector’s contribution is unimportant. Industry bears the enormous cost of clinical trials, regulatory filings, and manufacturing scale-up. But the picture that emerges is one of deep interdependence: basic science identifies what to target, and industry figures out how to hit it safely and at scale. Cut the basic research, and the pipeline of future targets dries up.
The mRNA Vaccine Story
The COVID-19 pandemic brought the value of basic science into unusually sharp public focus. The mRNA vaccines developed by Pfizer-BioNTech and Moderna were designed, tested, and authorized within about a year of the virus’s genetic sequence being published. That speed was extraordinary, but it was only possible because of decades of prior basic research into mRNA biology, lipid nanoparticle delivery, and coronavirus spike protein structure.7PubMed Central. What Is Basic Science and Why Does It Matter?
Biochemist Katalin Karikó spent years in the 1990s and 2000s studying how to modify synthetic mRNA so the human immune system would not immediately destroy it. Her work attracted little attention and even less funding at the time, because there was no obvious product waiting at the end. Similarly, structural biologists studying coronavirus spike proteins after the SARS and MERS outbreaks had no way of knowing that a novel coronavirus would emerge in 2019. When it did, their prior work meant scientists already understood the three-dimensional shape of the spike protein and knew how to stabilize it in a form that would provoke a strong immune response.
The mRNA vaccine timeline is often held up as proof that science can move fast when it needs to. That is true, but the more accurate lesson is that the speed was purchased by decades of slow, unglamorous basic research. Without that accumulated knowledge, vaccine developers would have been starting from scratch, and the timeline would have looked very different.
Why “Useless” Findings Still Count
One persistent challenge for basic science is that many individual studies seem to lead nowhere. A researcher spends years understanding some molecular pathway, publishes the results, and the work is never obviously applied to anything. From a funder’s perspective, this can look wasteful. From a scientific perspective, these apparently dead-end findings serve at least two vital functions.
First, they narrow the space of possibilities for future researchers. Knowing that a particular approach does not work, or that a specific mechanism does not operate the way people assumed, saves time and money for everyone who comes after. The problem is that these negative or null findings are much less likely to get published. Studies with positive results are far more likely to appear in journals, which means the scientific record over-represents what works and under-represents what does not. When negative results go unpublished, other researchers waste time and resources repeating studies that have already been done and found nothing.8PubMed Central. Publication bias – Importance of studies with negative results! That distortion is called publication bias, and it is one of the real structural problems in how science communicates with itself.
Second, basic findings that appear useless today may become critical when combined with discoveries that have not been made yet. The history of science is full of examples where a finding sat dormant for years before someone in a completely different field realized it solved their problem. The bacterial immune system that became CRISPR is one example. The observation that certain molds kill bacteria, which eventually became penicillin, is another. You cannot predict in advance which “useless” findings will turn out to be transformative, which is precisely the argument for funding basic science broadly rather than betting only on research with obvious near-term applications.
What the Public Actually Thinks
Despite occasional political debates about whether taxpayer money should fund research without guaranteed returns, public support for basic science in the United States has been remarkably stable. Survey data spanning three decades show that most Americans believe science and technology create more opportunities for the next generation, and they support federal funding for basic research even when they do not expect it to produce immediate benefits. In 2022, about 88% of U.S. adults agreed that scientific research advancing the frontiers of knowledge deserves government support.9National Center for Science and Engineering Statistics (NCSES). Science and Engineering Indicators: Public Perceptions of Science and Technology
That level of support is worth noting because political rhetoric sometimes suggests the public wants science to justify itself in immediate, practical terms. The survey data suggest otherwise: most people intuitively understand that exploration without a guaranteed payoff is how breakthroughs happen. The disconnect tends to arise not at the level of public opinion but at the level of budget allocation, where short-term political cycles can make it difficult to sustain the kind of patient, long-horizon investment that basic science requires.
Training the Next Generation of Scientists
Basic science does not only produce knowledge and potential technologies. It also produces people. Graduate students and postdoctoral researchers working in basic science labs learn how to formulate questions, design experiments, interpret complex data, and communicate findings. These skills turn out to be valuable far beyond academia. PhD graduates trained in basic research go on to work in industry R&D, government agencies, biotech startups, consulting, and science policy.
How trainees are funded during their graduate work can shape where they end up. Research looking at U.S. PhD graduates found that those primarily supported as research assistants on faculty grants were about 4.6 percentage points more likely to take a U.S. R&D job compared to peers from the same program and graduation year who were primarily supported by fellowships or traineeships.10ScienceDirect. Training the scientific workforce: Does funding mechanism matter? That difference may sound small, but at the scale of thousands of graduates each year, it shapes the composition of the country’s scientific workforce.
The broader point is that basic science labs function as training grounds. Even when the specific research project a graduate student works on never leads to a practical application, the student themselves becomes a practical application of the investment. They carry the skills, habits of thinking, and technical knowledge into whatever work they do next.
The Dual-Use Problem
Not every consequence of basic science is welcome. Research aimed at understanding how the world works can sometimes produce knowledge that is dangerous in the wrong hands. This is the dual-use dilemma: the same scientific insight can be used for both beneficial and harmful purposes.11PubMed Central. Governance of dual-use research: an ethical dilemma
The most discussed examples tend to involve infectious disease research. Understanding how a pathogen spreads or what makes it more virulent can help public health agencies prepare for outbreaks. That same understanding could, in theory, help someone engineer a more dangerous version of the pathogen. Nuclear physics offers an older and starker example: the same basic understanding of atomic fission that powers nuclear reactors also powers nuclear weapons.
The existence of dual-use risks does not argue against doing basic science. It argues for governance structures that match the pace and scope of scientific progress. Most researchers never work on anything with dual-use potential, and the overwhelming majority of basic science poses no safety concern at all. But for the fraction that does, the challenge is to allow the research to proceed in ways that capture the benefits while minimizing the risks. That challenge is genuinely difficult, and scientists, ethicists, and policymakers are still working out the best approaches. The tension is real, and pretending it does not exist would be as irresponsible as using it as a reason to stop doing basic research altogether.
Knowledge as an End in Itself
Most arguments for basic science lean on its eventual practical payoff, and the evidence for that payoff is strong, as the examples above illustrate. But there is a separate, older argument that is worth taking seriously: understanding the world has value even if no application ever materializes.
Philosophers of science have long argued that true beliefs are valued for their own sake, and that this kind of valuation is not a quirky preference but a core feature of the scientific worldview.12Oxford Scholarship Online. The Intrinsic Value of Scientific Knowledge and Understanding People care about knowing what distant galaxies are made of, whether there was ever life on Mars, and how consciousness arises in the brain. These questions are not asked because the answers will make anyone richer or healthier. They are asked because humans are the kind of creatures that want to know.
This intrinsic-value argument is harder to defend in a budget hearing than pointing to drugs or vaccines. But it explains why civilizations have invested in knowledge generation for millennia, long before the concept of “return on investment” existed. When people visit a planetarium, read about deep-sea ecosystems, or follow the latest images from a space telescope, they are participating in a tradition that treats understanding as worthwhile on its own terms. Basic science, at its core, is the professional version of that same impulse. The practical breakthroughs it occasionally delivers are a spectacular bonus, but they are not the only reason it matters.